Article
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Aug 2009
Ramoz Nicolas, Boni Claudette, Downing Anncatherine M, Close Sandra L, Peters Sandra L, Prokop Angela M, Allen Albert J, Hamon Michel, Purper-Ouakil Diane, Gorwood Philip
Abstract excerpt
Atomoxetine is a specific inhibitor of the norepinephrine transporter (NET) that has demonstrated efficacy in the treatment of children with attention-deficit hyperactivity disorder (ADHD). We investigated whether polymorphisms in the NET/SLC6A2 gene may influence atomoxetine response in ADHD. Two independent cohorts of 160 and 105 ADHD children treated for 6 weeks with atomoxetine (0.5-1.8 mg/kg per day) were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.